Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 19 février 2020
Doi : 10.1016/j.jaad.2019.12.071
Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series
 

Sujay Khandpur, MD a, , Prateek Sondhi, MD a, Neha Taneja, MD a, Preeti Sharma, MSc a, Dayasagar Das, MSc b, Alpana Sharma, PhD b, Vishnubatla Sreenivas, MD c
a Department of Dermatology and Venereology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 
b Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 
c Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 

Correspondence and reprint requests to: Sujay Khandpur, MD, Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Dermatology and VenereologyAll India Institute of Medical SciencesNew DelhiIndia

 Funding sources: None.
 Conflicts of interest: This was an investigator-initiated trial. The drug adalimumab biosimilar (Exemptia) was provided by Zydus Biovation (division of Cadila Health Care) free of cost to all patients. Zydus Biovation had no interference in the design, conduct, and analysis of the study.
 IRB approval status: Reviewed and approved by All India Institute of Medical Sciences Ethics Committee, New Delhi (approval reference number IEC-83/08.01.2016, RP-11/2016).


Top of the page

© 2020  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@